Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for AMRN
-0.03 (-0.95%)
After Hours: 3.12 -0.02 (-0.64%)
Apr 25, 5:27PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.13 - 3.24
52 week 1.50 - 3.65
Open 3.17
Vol / Avg. 2.63M/1.04M
Mkt cap 849.98M
P/E     -
Div/yield     -
EPS -0.41
Shares 270.70M
Beta 0.82
Inst. own 42%
May 3, 2017
Q1 2017 Amarin Corporation PLC Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 28, 2017
Q4 2016 Amarin Corporation PLC Earnings Release
Feb 28, 2017
Q4 2016 Amarin Corporation PLC Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -70.95% -66.38%
Operating margin -33.24% -50.45%
EBITD margin - -49.88%
Return on average assets -61.02% -50.76%
Return on average equity - -
Employees 215 -
CDP Score - -


Upper Pembroke Pembroke House 2, South Lotts Road
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 55
Bio & Compensation  - Reuters
Michael Wayne Kalb CPA Chief Financial Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Age: 53
Bio & Compensation  - Reuters
Michael J. Farrell Vice President - Finance (principal accounting officer and principal financial officer)
Age: 37
Bio & Compensation  - Reuters
Craig B. Granowitz M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 54
Bio & Compensation  - Reuters
Patrick J. O'Sullivan Non-Executive Independent Director
Age: 74
Bio & Compensation  - Reuters